Filing Details

Accession Number:
0001209191-21-012207
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-18 21:00:34
Reporting Period:
2021-02-16
Accepted Time:
2021-02-18 21:00:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080709 Arena Pharmaceuticals Inc ARNA Pharmaceutical Preparations (2834) 232908305
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657494 Vincent Aurentz C/O Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego CA 92121
Executive Vp And Cbo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-16 2,500 $14.60 29,500 No 4 M Direct
Common Stock Acquisiton 2021-02-16 24 $35.60 29,524 No 4 M Direct
Common Stock Disposition 2021-02-16 2,524 $85.00 27,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-02-16 2,500 $0.00 2,500 $14.60
Common Stock Employee Stock Option (right to buy) Disposition 2021-02-16 24 $0.00 24 $35.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
77,000 2024-02-13 No 4 M Direct
94,976 2025-01-19 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
  2. The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
  3. The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.